Skip to content

A verification study for the reducing effect of the consumption of the test-food on LDL cholesterol

A verification study for the reducing effect of the consumption of the test-food on LDL cholesterol: A randomized double-blind placebo-controlled, parallel-group trial - A verification study for the reducing effect of the consumption of the test-food on LDL cholesterol

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040493
Enrollment
52
Registered
2020-05-22
Start date
2020-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: 12 weeks Test food: Capsule containing fish oil Administration: Take three capsules per day at any time during the day. * If you forget to take the test food, take it as soon as you rem

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic Nerima Medical Association, Minami-machi Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult subjects 2. Subjects whose LDL cholesterol level was high in the most recent health checks 3. Subjects who are judged as eligible to participate in the study by the physician 4. Subjects whose LDL cholesterol levels are 120 mg/dL or more and 139 mg/dL or less at screening

Exclusion criteria

Exclusion criteria: 1. Subjects undergoing medical treatment or having a medical history of malignant tumor, heart failure, or myocardial infarction 2. Subjects carrying a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage as part of their daily intake 5. Subjects regularly taking medications (including herbal medicines) and supplements 6. Subjects allergic to medications and/or the test-food-related products 7. Subjects who are pregnant, lactating, or intending to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 9. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
1. The measured value of LDL cholesterol at 12 weeks after the start of test-food consumption

Secondary

MeasureTime frame
1. The measured value of LDL cholesterol at four and eight weeks after the start of test-food consumption 2. The amount of changes of LDL cholesterol between before and four, eight and 12 weeks after the start of test-food consumption 3. The rate of changes of LDL cholesterol between before and four, eight and 12 weeks after the start of test-food consumption 4. The ratio of number of subjects whose LDL cholesterol levels are less than 120 mg/dL at 12 weeks after the start of test-food consumption 5-1. The measured values of the following items 5-2. The amount of changes of the following items [Items] total cholesterol, HDL cholesterol, flow mediated dilation (FMD), maximum expansion width of vessel, diameter of vessels at rest, blood flow velocity, visibility of vessels, density of vessels, diameter of vessels, distance between vessels and length of vessels 6. The ratio of number of subjects whose blood vessels are straight and shaped like hairpins, twisted and various shapes, irregular such as branches, or look short (hard to see) after four, eight and 12 weeks after the start of test-food consumption 7. The measured values of each item of original questionnaires at four, eight and 12 weeks after the start of test-food consumption

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026